HYPOTENSIVE ACTION OF DUP-753, AN ANGIOTENSIN-II ANTAGONIST, IN SPONTANEOUSLY HYPERTENSIVE RATS - NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONISTS .10.

被引:241
作者
WONG, PC
PRICE, WA
CHIU, AT
DUNCIA, JV
CARINI, DJ
WEXLER, RR
JOHNSON, AL
TIMMERMANS, PBMWM
机构
[1] Du Pont De Nemours/Company, Medical Products Department, Pharmaceutical Res. Division, Wilmington, DE 19880-0400
关键词
angiotensin receptor; antihypertensive agents; hypotension; renin-angiotensin system; spontaneously hypertensive rats;
D O I
10.1161/01.HYP.15.5.459
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
In conscious 18-21-week-old spontaneously hypertensive rats, DuP 753, a nonpeptide angiotensin II receptor antagonist, given orally at 3 and 10 mg/kg or intravenously at 3, 10, and 30 mg/kg, reduced blood pressure dose dependently. It did not alter heart rate at these doses. At 10 mg/kg i.v., DuP 753 decreased blood pressure significantly for at least 24 hours, suggesting a long duration of the antihypertensive effect. Unlike saralasin, DuP 753 did not cause a transient increase in blood pressure. The acute antihypertensive efficacy of DuP 753 was greater than that of captopril. Our data indicate that, for captopril to reduce blood pressure to a similar extent as that of DuP 753, it would need to be supplemented by a diuretic. DuP 753 did not have an acute diuretic effect. Bilateral nephrectomy, but not inhibition of prostaglandin synthesis, abolished the antihypertensive effect of DuP 753, suggesting that the antihypertensive effect of DuP 753 is dependent on an active renin-angiotensin system. Furthermore, DuP 753 inhibited the pressor response to angiotensin II but not the responses to norepinephrine, vasopressin, and Bay K 8644 (a calcium agonist). As neither DuP 753 nor captopril decreased blood pressure acutely in Wistar-Kyoto normotensive rats, our results suggest that the renin-angiotensin system plays a significant role in the control of blood pressure in spontaneously hypertensive rats.
引用
收藏
页码:459 / 468
页数:10
相关论文
共 33 条
  • [1] EFFECTS OF CHRONIC TREATMENT WITH CAPTOPRIL (SQ 14,225), AN ORALLY ACTIVE INHIBITOR OF ANGIOTENSIN I-CONVERTING ENZYME, IN SPONTANEOUSLY HYPERTENSIVE RATS
    ANTONACCIO, MJ
    RUBIN, B
    HOROVITZ, ZP
    LAFFAN, RJ
    GOLDBERG, ME
    HIGH, JP
    HARRIS, DN
    ZAIDI, I
    [J]. JAPANESE JOURNAL OF PHARMACOLOGY, 1979, 29 (02) : 285 - 294
  • [2] ANTONACCIO MJ, 1979, CLIN SCI, V57, P1278
  • [3] CIRCULATING AND TISSUE ANGIOTENSIN SYSTEMS
    CAMPBELL, DJ
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1987, 79 (01) : 1 - 6
  • [4] CARINI DJ, 1989, Patent No. 324377
  • [5] CHIU AT, 1989, J PHARMACOL EXP THER, V250, P867
  • [6] CHIU AT, 1990, J PHARMACOL EXP THER, V252, P711
  • [7] NON-PEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONISTS .2. PHARMACOLOGY OF S-8308
    CHIU, AT
    CARINI, DJ
    JOHNSON, AL
    MCCALL, DE
    PRICE, WA
    THOOLEN, MJMC
    WONG, PC
    TABER, RI
    TIMMERMANS, PBMWM
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 157 (01) : 13 - 21
  • [8] CODY RP, 1985, APPLIED STATISTICS S
  • [9] SIGNIFICANCE OF THE VASCULAR RENIN-ANGIOTENSIN PATHWAY
    DZAU, VJ
    [J]. HYPERTENSION, 1986, 8 (07) : 553 - 559
  • [10] Furakawa Y, 1982, U. S. Patent, Patent No. [4340 598, 4355 040, 4340598]